Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors

Ye, Tong; Li, Feng; Ma, Guanghui; Wei, Wei

doi:10.1016/j.addr.2021.113927

Cited by 36 publications

(19 citation statements)

References 215 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autologous cell-derived vaccine has the advantage of possessing abundance and breadth of an antigen source. , However, a low immunogenicity of autologous cell derivatives represents a huge challenge, which requires the codelivery of adjuvants or immunostimulants . Here, to confer the self-adjuvanting attribute, oncolysis was induced in autologous cells by treating with LTX-315, an oncolytic peptide (OP) that closely mimicked oncolytic virus by recapitulating its cationic and amphipathic nature. , …”

Section: Resultsmentioning

confidence: 99%

“…Regarding the aforementioned issues, an autologous tumor cell vaccine may be an option well-suited to post-surgical management, since it self-provides a full set of tumor-associated patient-specific antigen epitopes. , Indeed, such a consideration has given rise to innovative attempts of developing a hydrogel matrix that encapsulates photosensitizer-loaded or coated cancer cells from resected tumors. After irradiation following the implantation in the surgical bed, the autologous tumor cells were transformed into an immunogenic vaccine and elicited a specific response against residual microtumors for personalized therapy. , Inspired by this, instead of turning tumors into a vaccine by inducing onsite oncolysis, we proposed to take one step ahead of current oncolytic therapy by locally delivering autologous cancer cells succumbing to oncolysis (ACCO) as an antitumor vaccine.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis

Zhang

Zhou

et al. 2022

ACS Nano

View full text Add to dashboard Cite

Tumor surgery can create an inflammatory trauma to aggravate residual tumor “seed” to colonize pre-metastatic niches (PMNs) “soil” at secondary sites, thereby promoting post-operative metastasis. However, two-pronged strategies for post-surgical elimination of asynchronous “seeds” and “soil” at different regions are currently lacking. Here, we have designed a hydrogel that can be injected into a resection cavity, where it immediately forms a scaffold and gradually degrades responding to enriched reactive oxygen species at adjacent trauma for local delivery and on-demand release of autologous cancer cells succumbing to oncolysis (ACCO) and anti-inflammatory agent. The autologous cell source self-provides a whole array of tumor-associated antigens, and the oncolysis orchestration of a subcellular cascade confers a self-adjuvanting property, together guaranteeing high immunogenicity of the ACCO vaccine that enables specific antitumor immunization. In parallel, inflammation alleviation exerted bidirectional functions to reshape the local immune landscape and resuscitate ACCO, leading to the eradication of residual tumor “seeds” while simultaneously intercepting the “seed–soil” crosstalk to normalize distant lung leading to regression of pre-existing PMN “soil”. As a result, regional and metastatic recurrence were completely thwarted. Together, this framework synchronizing oncolysis immunization and inflammation alleviation provides an effective option for post-operative suppression of metastasis.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis

Zhang

Zhou

et al. 2022

ACS Nano

View full text Add to dashboard Cite

show abstract

“…To date, two major strategies have been developed: one is the use of autologous tumor cells and the other is synthetic neoantigen predicted by computerized algorithms. [ 225a,226 ] On the one hand, vaccines based on autologous tumor cells and engineered cell components that prepared by ex vivo treatment or ICD contain almost all TAAs, which are easy manufacturing. However, it should be noted that the use of tumor cell lysate could increase the complexity of clinical translation.…”

Section: Challenge and Prospectivementioning

confidence: 99%

“…[ 227 ] Thus, computational and experimental pipelines have been considered as a major method for identifying personalized neoantigens in real‐time. [ 226 ] Compared to identified tumor‐self TAAs, neoantigens are more endogenous and close to naturally existed antigens in tumor, which have been validated with higher immunogenicity in preclinical and clinical studies. Additionally, the number and type of neoantigens are unique to each lesion, which might necessitate a personalized immunotherapeutic approach.…”

Section: Challenge and Prospectivementioning

confidence: 99%

Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy

Ruan

Huang

et al. 2022

Advanced Science

View full text Add to dashboard Cite

The past decade has witnessed the explosive development of cancer immunotherapies. Nevertheless, low immunogenicity, limited specificity, poor delivery efficiency, and off-target side effects remain to be the major limitations for broad implementation of cancer immunotherapies to patient bedside. Encouragingly, advanced biomaterials offering cell-specific modulation of immunological cues bring new solutions for improving the therapeutic efficacy while relieving side effect risks. In this review, focus is given on how functional biomaterials can enable cell-specific modulation of cancer immunotherapy within the cancer-immune cycle, with particular emphasis on antigen-presenting cells (APCs), T cells, and tumor microenvironment (TME)-resident cells. By reviewing the current progress in biomaterial-based cancer immunotherapy, here the aim is to provide a better understanding of biomaterials' role in targeting modulation of antitumor immunity step-by-step and guidelines for rationally developing targeting biomaterials for more personalized cancer immunotherapy. Moreover, the current challenge and future perspective regarding the potential application and clinical translation will also be discussed.

show abstract

“…In the past few years, immunogenic cell death (ICD) has received much attention for boosting anti-neoplastic immune responses. As a form of regulated cell death, ICD can coordinate the complex cell-to-cell communication between dying CCs and immune cells to sequentially trigger antitumor innate immunity and adaptive immunity ( 10 - 12 ). Interestingly, under diseased conditions, like cancer, the cellular apoptosis involved in the continuous cellular turnover is likely to be non-immunogenic or even tolerogenic.…”

Section: Introductionmentioning

confidence: 99%

Inducing immunogenic cell death in immuno-oncological therapies

Ti¹,

Yan²,

Wei³

et al. 2022

Chinese Journal of Cancer Research

View full text Add to dashboard Cite

Immunotherapy has revolutionized cancer treatment and substantially improved patient outcomes with respect to multiple types of tumors. However, most patients cannot benefit from such therapies, mainly due to the intrinsic low immunogenicity of cancer cells (CCs) that allows them to escape recognition by immune cells of the body. Immunogenic cell death (ICD), which is a form of regulated cell death, engages in a complex dialogue between dying CCs and immune cells in the tumor microenvironment (TME), ultimately evoking the damage-associated molecular pattern (DAMP) signals to activate tumor-specific immunity. The ICD inducers mediate the death of CCs and improve both antigenicity and adjuvanticity. At the same time, they reprogram TME with a “cold-warm-hot” immune status, ultimately amplifying and sustaining dendritic cell- and T cell-dependent innate sensing as well as the antitumor immune responses. In this review, we discuss how to stimulate ICD based upon the biological properties of CCs that have evolved under diverse stress conditions. Additionally, we highlight how this dynamic interaction contributes to priming tumor immunogenicity, thereby boosting anticancer immune responses. We believe that a deep understanding of these ICD processes will provide a framework for evaluating its vital role in cancer immunotherapy.

show abstract

Enhancing therapeutic performance of personalized cancer vaccine via delivery vectors

Cited by 36 publications

References 215 publications

Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis

Trauma-Responsive Scaffold Synchronizing Oncolysis Immunization and Inflammation Alleviation for Post-Operative Suppression of Cancer Metastasis

Advanced Biomaterials for Cell‐Specific Modulation and Restore of Cancer Immunotherapy

Inducing immunogenic cell death in immuno-oncological therapies

Contact Info

Product

Resources

About